Fuyuan Pharmaceutical announced that the company recently received a rotigotin patch “Drug Registration Certificate” issued by the State Drug Administration to approve the production of the drug. This certification is considered to have passed the consistency evaluation. This drug is a prescription drug. It is a class of 4 chemicals. It is used as a single agent for the early symptoms and signs of idiopathic Parkinson's disease, or used in combination with levodopa at all stages of the course of the disease. As of the announcement date, the company has invested a total of 157.77,900 yuan in research and development of this drug. This certification will enrich the company's product line, but there is uncertainty about its sales situation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.